I
Ira Pastan
Researcher at Laboratory of Molecular Biology
Publications - 1304
Citations - 113191
Ira Pastan is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Immunotoxin & Pseudomonas exotoxin. The author has an hindex of 160, co-authored 1286 publications receiving 110069 citations. Previous affiliations of Ira Pastan include Heidelberg University & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
COLLOID DROPLET FORMATION IN DOG THYROID IN VITRO: Induction by Dibutyryl Cyclic-AMP
Ira Pastan,Seymour H. Wollman +1 more
TL;DR: Dibutyryl c-AMP, like TSH, causes the formation of pseudopods and intracellular colloid droplets when incubated with dog thyroid slices, and is shown to stimulate glucose oxidation in dog slices and phospholipid metabolism in beef thyroid slices.
Journal ArticleDOI
Mesothelin is shed from tumor cells.
TL;DR: The authors found that the SMP in ascites from a patient with ovarian carcinoma contained the sequence of extracellular domain of a soluble mesothelin protein.
Journal ArticleDOI
Cytotoxicity of the anti‐CD22 immunotoxin HA22 (CAT‐8015) against paediatric acute lymphoblastic leukaemia
Francis Mussai,Dario Campana,Deepa Bhojwani,Maryalice Stetler-Stevenson,Seth M. Steinberg,Alan S. Wayne,Ira Pastan +6 more
TL;DR: HA22, at concentrations achievable in patients, is highly cytotoxic to B‐lineage ALL cells, providing a strong rationale for clinical testing of this agent in children with drug‐resistant ALL and offers the potential to reduce morbidities of treatment while improving outcome.
Journal Article
Reduction of the Nonspecific Animal Toxicity of Anti-Tac(Fv)-PE38 by Mutations in the Framework Regions of the Fv Which Lower the Isoelectric Point
TL;DR: It is hypothesized that the overall positive charge on the Fv portion of anti-Tac(Fv)-PE38 contributes to nonspecific binding to liver cells and results in dose-limiting liver toxicity, and if this decreased toxicity occurs in humans, it should greatly increase the clinical utility of this immunotoxin.
Journal ArticleDOI
In Vitro and in Vivo Cytotoxic Activities of Recombinant Immunotoxin 8H9(Fv)-PE38 against Breast Cancer, Osteosarcoma, and Neuroblastoma
TL;DR: 8H9(dsFv)-PE38 is a candidate for further development as a therapeutic agent for breast cancers, osteosarcomas, and neuroblastomas and shows that a dose that causes significant tumor regressions in mice is well tolerated by monkeys.